These should include reintroduction of routine CD4 count testing of ≤200 lells/μL to diagnose AHD and other tests in the package of care to rapidly identify and treat, or exclude, active TB or cryptococcal disease without delaying ART initiation for most patients [41]. The gene discussed is CD4; the disease is tuberculosis.